BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 7752223)

  • 1. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
    Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
    J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
    Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
    J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation.
    Reddy CD; Dasgupta P; Saikumar P; Dudek H; Rauscher FJ; Reddy EP
    Oncogene; 1992 Oct; 7(10):2085-92. PubMed ID: 1408152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
    Davis LJ; Halazonetis TD
    Oncogene; 1993 Jan; 8(1):125-32. PubMed ID: 8423990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NMR solution structure of a mutant of the Max b/HLH/LZ free of DNA: insights into the specific and reversible DNA binding mechanism of dimeric transcription factors.
    Sauvé S; Tremblay L; Lavigne P
    J Mol Biol; 2004 Sep; 342(3):813-32. PubMed ID: 15342239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA binding by N- and L-Myc proteins.
    Ma A; Moroy T; Collum R; Weintraub H; Alt FW; Blackwell TK
    Oncogene; 1993 Apr; 8(4):1093-8. PubMed ID: 8455937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.
    Crouch DH; Fisher F; La Rocca SA; Goding CR; Gillespie DA
    Nucleic Acids Res; 2005; 33(16):5235-42. PubMed ID: 16166655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
    Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
    Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of transcriptional repression by max homodimers.
    Yin X; Grove L; Prochownik EV
    Oncogene; 1998 May; 16(20):2629-37. PubMed ID: 9632139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
    Amati B; Dalton S; Brooks MW; Littlewood TD; Evan GI; Land H
    Nature; 1992 Oct; 359(6394):423-6. PubMed ID: 1406955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
    Beaulieu ME; McDuff FO; Frappier V; Montagne M; Naud JF; Lavigne P
    J Mol Recognit; 2012 Jul; 25(7):414-26. PubMed ID: 22733550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain.
    Ferré-D'Amaré AR; Prendergast GC; Ziff EB; Burley SK
    Nature; 1993 May; 363(6424):38-45. PubMed ID: 8479534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taking myc to the max.
    Turner R
    Nat Struct Biol; 2003 Mar; 10(3):157. PubMed ID: 12605219
    [No Abstract]   [Full Text] [Related]  

  • 19. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
    Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
    Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA binding of Myc/Max/Mad network complexes to oligonucleotides containing two E box elements: c-Myc/Max heterodimers do not bind DNA cooperatively.
    Vervoorts J; Lüscher B
    Biol Chem; 1999 Sep; 380(9):1121-6. PubMed ID: 10543451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.